Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD NIS793 - TGFẞ1 inhibitor Study Indication Phase Patients Primary Outcome Measures NCT04935359 (CNIS793B12301) 1L Pancreatic cancer Phase 3 490 ☐ Arms Intervention " Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment Randomized part: Overall survival (OS) Arm 1: Experimental: Safety run-in part: NIS793+gemcitabine+nab-paclitaxel In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel " Arm 2: Experimental: Randomized part: NIS793+gemcitabine+nab-paclitaxel Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel Arm 3: Placebo Comparator: Randomized part: placebo+gemcitabine+nab- paclitaxel " Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first line treatment Target Patients Read-out Milesstone(s) 2026 Publication TBD 108 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation